HDAC6 and Charcot-Marie-Tooth disease: Continuing from this mile stone in the development of potent and selective inhibitors of the deacetylating function of HDAC6, we set up a screen to identify new small molecules with improved pharmacological properties in the exploration of a potential pharmacological therapy for CMT.